SAVE (super-dose anti-VEGF) trial: 2.0 mg ranibizumab for recalcitrant neovascular age-related macular degeneration: 1-year results

Research output: Contribution to journalArticle

20 Scopus citations

Fingerprint Dive into the research topics of 'SAVE (super-dose anti-VEGF) trial: 2.0 mg ranibizumab for recalcitrant neovascular age-related macular degeneration: 1-year results'. Together they form a unique fingerprint.

Medicine & Life Sciences